| Literature DB >> 35830886 |
Margaret von Mehren1, John M Kane2, Mark Agulnik3, Marilyn M Bui4, Janai Carr-Ascher5, Edwin Choy6, Mary Connelly7, Sarah Dry8, Kristen N Ganjoo9, Ricardo J Gonzalez4, Ashley Holder10, Jade Homsi11, Vicki Keedy12, Ciara M Kelly13, Edward Kim14, David Liebner7, Martin McCarter15, Sean V McGarry16, Nathan W Mesko17, Christian Meyer18, Alberto S Pappo19, Amanda M Parkes20, Ivy A Petersen21, Seth M Pollack22, Matthew Poppe23, Richard F Riedel24, Scott Schuetze25, Jacob Shabason26, Jason K Sicklick27, Matthew B Spraker28, Melissa Zimel29, Lisa E Hang30, Hema Sundar30, Mary Anne Bergman30.
Abstract
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recommendations, and reviews the evidence to support the guidelines recommendations.Entities:
Mesh：
Year: 2022 PMID： 35830886 DOI： 10.6004/jnccn.2022.0035
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 12.693